ECE2017 Eposter Presentations: Pituitary and Neuroendocrinology Pituitary - Clinical (145 abstracts)
1Clinic of Endocrinology, University of Medicine and Pharmacy Victor Babes, Timisoara, Romania; 2University of Medicine and Pharmacy Victor Babes, Timisoara, Romania.
The study group was represented by 155 cases of pituitary insufficiency (age: 37.21±16.05; F/M=116/39) hospitalized in the Clinic of Endocrinology Timişoara during the period 20062014. The cases were classified into ethiopatogenic groups, as follows: iatrogenic pituitary insufficiency (23.87%), tumor compression (21.29%), ischemia (14.84%), idiopathic hypogonadotropic hypogonadism (3.87%), congenital pituitary insufficiency (6.45%), empty sella (6.45%), functional pituitary insufficiency (23.23%). In majority, the studied cases presented hypogonadism (95.48%), while hypothyroidism was found in 65.16% patients and 50.32% of the cases presented adrenal insufficiency. Neurological signs caused by the tumoral mass were found in 42.58% cases. The ischemic and congenital forms of the pituitary insufficiency associated mostly panhypopituitarism (100%, respectively 50%), while the iatrogenic form and those caused by tumor compression presented in high percentages partial pituitary insufficiency. The comparison of the hormonal parameters (ethiopatogenic groups) revealed: significant inferior serum levels of testosterone in the congenital form and empty sella vs tumor compression (P < 0.05); significant inferior levels of the serum estradiol (P < 0.01) in congenital panhypopituitarism vs functional secondary hypogonadism; significant inferior levels of the serum TSH (P < 0.05) in patients with pituitary insufficiency caused ischemia vs tumor compression; significant inferior levels of FT4 (P < 0.05) in empty sella and ischemic form vs iatrogenic pituitary insufficiency. The applied therapy targeted the cause of the hypopituitarism and the hormonal substitution.